MarAprMayJun
↩ TodayMon23Mar
Tue24Mar
Wed25Mar
Thu26Mar
Fri27Mar
Sat28Mar
Sun29Mar
Mon30Mar
Tue31Mar
Wed1Apr
Thu2Apr
Fri3Apr
Sat4Apr
Sun5Apr
Mon6Apr
Tue7Apr
Wed8Apr
Fri10Apr
Sat11Apr
Mon13Apr
Tue14Apr
Wed15Apr
Thu16Apr
Fri17Apr
Sat18Apr
Sun19Apr
Mon20Apr
Tue21Apr
Wed22Apr
Thu23Apr
Fri24Apr
Sat25Apr
Sun26Apr
Mon27Apr
Tue28Apr
Wed29Apr
Thu30Apr
Fri1May
Sat2May
Sun3May
Mon4May
Tue5May
Wed6May
Thu7May
Fri8May
Sat9May
Sun10May
Mon11May
Tue12May
Wed13May
Thu14May
Fri15May
Sat16May
Sun17May
Mon18May
Tue19May
Wed20May
Thu21May
Fri22May
Sat23May
Sun24May
Mon25May
Tue26May
Wed27May
Thu28May
Fri29May
Sat30May
Sun31May
Mon1Jun
Tue2Jun
Wed3Jun
Thu4Jun
Fri5Jun
Sat6Jun
Sun7Jun
Mon8Jun
Tue9Jun
Wed10Jun
Thu11Jun
Fri12Jun
Sat13Jun
Sun14Jun
Mon15Jun
Tue16Jun
Wed17Jun
Thu18Jun
Fri19Jun
Sat20Jun
Sun21Jun
Mon22Jun
Wed24Jun
Thu25Jun
Fri26Jun
Sat27Jun
15 papers read · 14 surfaced · 2 stood out
Today's lead · Treatment Innovation
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or…
Adding penpulimab to chemotherapy more than doubled disease progression time in nasopharyngeal carcinoma patients with manageable side effects.
Huang S, Liu F, Qu S et al. · Signal Transduction and Targeted Therapy
9/10
Impact score
Time to impact (est.)
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Near-term implementable finding
Comparative efficacy of phase 2-3 therapies for non-cirrhotic…
Newer metabolic drugs show promise against fatty liver disease, though combination approaches may be needed since many patients don't respond to single agents.
Standard additionAssociation between treatment-emergent cytopenias and clinical…
Patients developing low blood cell counts during imetelstat treatment for bone marrow disease showed better responses, helping doctors interpret treatment progress.
Standard additionCabozantinib in patients with non-locally pretreated brain metastases…
Cabozantinib achieved 86% response rates as first-line treatment for brain tumors from kidney cancer, offering durable disease control.
Promising but preliminaryPonatinib inhibits LCK and PI3K signaling and promotes CD8(+) T stem…
Repurposing a leukemia drug to strengthen CAR-T cell persistence could enhance immunotherapy outcomes for cancer patients.